Evaluation of HER2DX Assay on Treatment Decisions in Patients With Early Stage HER2+ Breast Cancer: the HER2BREASTDX

RecruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

October 24, 2024

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Breast Cancer Early Stage Breast Cancer (Stage 1-3)

Interventions

DRUG

Neoadjuvant standard treatment for HER2+

NEOADJUVANT SETTING

DRUG

Adjuvant standard treatment for HER2+

ADJUVANT SETTING

Trial Locations (1)

RECRUITING

Istituto Europeo di Oncologia, Milan

All Listed Sponsors

lead

European Institute of Oncology

OTHER